"This positive opinion underlines two things", explains Dr. Henri Huttunen, Chief Scientific Officer of Herantis. "First, there is a dire need for novel treatments for ALS, which is
The reduction includes approximately 90 positions in the U.S. and Europe. No customer-facing positions within ARIAD’s commercial or medical affairs organizations are included in this action. This reduction
The initial focus of the JV will be immediately advancing ProscaVax, OncBioMune’s novel prostate cancer vaccine combining a tumor-associated antigen with biological adjuvants, into a Phase 2A/2B clinical
Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the management
The FDA Prescription Drug User Fee Act ("PDUFA") goal date for a decision is September 14, 2016. Aralez CEO Adrian Adams said: "The acceptance of our NDA for
The trial, conducted in collaboration with the EU-sponsored UNISEC consortium, is designed to evaluate the safety and immunogenicity of M-001 when used ahead of an avian influenza vaccine.
Under the license, ABBA will be able to use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies. Ligand is to receive an
Two separate Phase 2 clinical studies are evaluating the combination therapy as a co-formulated single intravitreal injection in patients with wet age-related macular degeneration or diabetic macular edema.
This acquisition will expand PuraCap’s world-class manufacturing expertise beyond soft gelatin capsules to include oral tablet & capsule dosage forms for both the US and global markets. Under
Stannsoporfin is a first in class heme oxygenase inhibitor that inhibits the formation of bilirubin and is in development for the treatment of hyperbilirubinemia in newborns. The study
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.